Optimizing psychedelic compounds for neuropsychiatric therapy
Neuropsychopharmacology
.
2021 Jul;46(8):1397-1398.
doi: 10.1038/s41386-021-01004-7.
Epub 2021 Apr 5.
Author
Scott M Thompson
1
Affiliation
1
Departments of Physiology and Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA. sthompson@som.umaryland.edu.
PMID:
33820954
PMCID:
PMC8209136
DOI:
10.1038/s41386-021-01004-7
No abstract available
Publication types
Research Support, N.I.H., Extramural
Review
MeSH terms
Hallucinogens* / therapeutic use
Lysergic Acid Diethylamide
Psilocybin
Substances
Hallucinogens
Psilocybin
Lysergic Acid Diethylamide
Grants and funding
R01 MH086828/MH/NIMH NIH HHS/United States